Targeted Degradation of NETs in Lupus with DNASE1L3 Deficiency

New England Journal of Medicine 2026

View at publisher
Authors: Tadej Avčin, Andreas Reiff, Maša Bizjak, Barbara Jenko Bizjan, Tina Vesel Tajnšek, Maruša Debeljak, Tyler Artner, Bernd Jilma, Christian Lood, Abdul Hakkim, Tobias A. Fuchs
DOI: 10.1056/nejmc2601997
Cited by: 1
References: 5

Abstract

Recombinant DNASE1L3 therapy reduced symptoms in a patient with severe lupus with DNASE1L3 deficiency. Antidrug antibodies caused effects to wane, but findings support NET-targeted therapy as a nonimmunosuppressive approach.

Fields of Study & Subjects

Calcium signaling and nucleotide metabolism PARP inhibition in cancer therapy DNA Repair Mechanisms

Publication details

Journal / source
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Volume
395
Issue
3
Pages
308–310
Publication date
15 July 2026
Language
EN